South Korea approved Pfizer's COVID-19 vaccine for use with children aged 5-11, the country's food and drug ministry revealed on Wednesday.
The Ministry of Food and Drug Safety experienced the vaccine from both inside and outside to review the safety and efficacy of the two-dose regimen, after reviewing Pfizer's clinical studies.
In addition, the ministry said the vaccine was found to be 90.7% effective in preventing COVID-19 in children aged 5 through 11. This authorization marks the first time for the agency to approve the use of COVID-19 vaccines for young children.
The Pfizer vaccine is administered as a two-dose primary series with a three-week interval period.
Meantime, South Korea recorded 137,227 daily virus cases as of 6 p.m. Wednesday, Yonhap News Agency reported.
Other than South Korea, France’s Haute Autorite de Sante (HAS) health regulator approved the Pfizer-BioNTech COVID-19 vaccine for all children aged 5-11.
Lise Alter, one of the doctors charged with the risk evaluation of new drugs, stated that the vaccine showed high efficacy among children.
“The HAS suggests that all parents who want it can have their children aged 5 to 11 years vaccinated,” Alter added.
In the same vein, Health Canada has also approved the use of Pfizer-BioNTech’s coronavirus vaccine for children ages 5 to 11.
In a news conference, Dr. Supriya Sharma, chief medical adviser at Health Canada, affirmed that this is very good news for adults and children alike.
“It provides another tool to protect Canadians and, to the relief of many parents, will help bring back a degree of normality to children’s lives, allowing them to more safely do the things that they have missed during the last 20 months,” Sharma added.
Follow the latest news on Google News
